Risk Warning: Leveraged products carry a high level of risk and may result in the loss of all your capital. Ensure you fully understand the risks before investing.
Risk Warning: Leveraged products carry a high level of risk and may result in the loss of all your capital. Ensure you fully understand the risks before investing.

Current region:

  • English
    ACTIVE
Other languages:
  • Español – Spanish
  • Português – Portuguese
  • English – International
  • Tiếng Việt – Vietnamese
  • Français – French
  • ไทย – Thai
  • العربية – Arabic
Risk Warning: Leveraged products carry a high level of risk and may result in the loss of all your capital. Ensure you fully understand the risks before investing.

AMD, Palantir, and Super Micro in Focus

U.S. stocks are in focus today as investors track key corporate updates across technology, healthcare, and energy. Palantir gained after raising its full-year forecast, while Hims came under pressure following its break with Novo Nordisk and weaker sales. BP also moved higher, supported by improved margins and fresh cost-cutting measures.

Key Points:

  • Palantir rises 6% after lifting its full-year forecast.
  • Hims dropped 10% following a break with Novo Nordisk and disappointing sales.
  • BP gains 2.5% on improved margins and announced cost cuts.

Palantir (PLTR): Momentum from Upward Guidance

Palantir gained 6% in premarket trading after reporting quarterly earnings that surpassed expectations and raising its full-year outlook. The company continues to benefit from growing demand for its AI-driven software offerings.

Hims & Hers (HIMS), Novo Nordisk (NVO): Declines on Partnership Fallout and Weak Results

Shares of Hims fell over 10% after missing revenue estimates. The stock was further pressured by tensions with Novo Nordisk, sparked by Hims’ offering of generic weight-loss medications via its platform.

Vertex Pharmaceuticals (VRTX): Setback Following Clinical Trial Decision

Vertex declined 14% in after-hours trading after announcing it will halt development of its experimental pain treatment, despite promising early-stage data. The decision underscores the company’s reliance on its late-stage pipeline.

DuPont de Nemours (DD): Strong Sales and Upbeat Outlook

DuPont rose 7% in premarket trading after exceeding sales projections and issuing guidance above analyst expectations. Its specialty materials division showed resilience amid uneven end-market demand.

BP (BP), Diageo (DEO): Gains Despite External Pressures

BP advanced 2.5% after reporting stronger profitability metrics and introducing additional cost-saving initiatives. Diageo added 2% despite forecasting a $200 million annual tariff impact.

Advanced Micro Devices (AMD), Super Micro (SMCI), Snap (SNAP): Key Earnings Ahead

Investors are watching earnings reports from AMD, Super Micro Computer, and Snap, all due Tuesday. These results will offer insight into demand trends for high-performance chips, server infrastructure, and social media platforms amid a still-recovering tech landscape.

Related posts

Debt to Tangible Net Worth Explained 

Debt to Tangible Net Worth Explained 

Evaluating a company’s financial health requires more than simply looking at how much debt it carries. Investors also need to

Technical Analysis-EN

EURUSD Slips Despite US Inflation

Attention centred on US inflation data this week, with investors looking for fresh signals on the Federal Reserve’s policy outlook

Technical Analysis-EN

EURPLN Faces Poland Trade Deficit

Poland’s economy continued to outperform much of the European Union in early 2026, with GDP expanding by around 3.5% despite